Cytokinetics' flagship program, aficamten, is a cardiac myosin inhibitor designed to treat hypertrophic cardiomyopathy (HCM), a condition characterized by thickening of the heart muscle.

Cytokinetics' flagship program, aficamten, is a cardiac myosin inhibitor designed to treat hypertrophic cardiomyopathy (HCM), a condition characterized by thickening of the heart muscle. The company ...

Citi launched its coverage of Cytokinetics (NASDAQ:CYTK) with a Buy recommendation, noting that the cardiac drug developer’s recent selloff is overdone given that its lead asset, aficamten ...

If you've ever owned or cared for cats, you know that they tend to have their unique way of doing things and their individual temperaments. Some cats are attached to your hip while others don't ...

The shares seem attractive at current levels, given the “substantial opportunity” for aficamten, which could exceed $3.6B in peak sales, the analyst tells investors in a research note.

Last year, cat owner Chelsea, of Denver, Colorado, noticed that her "old lady cat" named Hari appeared to be slowing down and was struggling to keep up with her feline siblings. Hari was rescued ...

The firm thinks the pressure on Cytokinetics’ shares may be overdone given what the firm sees as a competitive profile for aficamten. Truist has a Buy rating and $70 price target on Cytokinetics ...

When you buy through our links, Business Insider may earn an affiliate commission. Learn more Cats with severe flea infestations can suffer from skin damage, an allergic reaction, and anemia from ...